Gerald Strohmaier - Valneva SE VP Resource
| VALN Stock | USD 7.75 0.01 0.13% |
Insider
Gerald Strohmaier is VP Resource of Valneva SE ADR
| Address | 6 rue Alain Bombard, Saint-Herblain, France, 44800 |
| Phone | 33 2 28 07 37 10 |
| Web | https://valneva.com |
Valneva SE Management Efficiency
The company has return on total asset (ROA) of (0.1023) % which means that it has lost $0.1023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5829) %, meaning that it created substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to grow to -0.32. At this time, Valneva SE's Non Currrent Assets Other are very stable compared to the past year. As of the 25th of April 2024, Other Current Assets is likely to grow to about 53.2 M, while Total Assets are likely to drop about 252.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Bensen | Tyra Biosciences | 48 | |
| Edward MD | Third Harmonic Bio | 51 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Barbara Wood | Sellas Life Sciences | 61 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Ian Leitch | Opthea | 61 | |
| Robert Hudkins | Tyra Biosciences | 68 | |
| Filip MD | Monte Rosa Therapeutics | 49 | |
| Jim Doherty | Sage Therapeutic | N/A | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| CPA CPA | Opthea | 63 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Christopher Benecchi | Sage Therapeutic | 52 | |
| David Pompliano | Revolution Medicines | N/A | |
| Ronald Swanson | Tyra Biosciences | 60 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Gregg Keaney | Third Harmonic Bio | N/A | |
| BS CPA | InhibrxInc | 42 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.1 |
Valneva SE ADR Leadership Team
Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Dequenne, Chief Officer | ||
| Frederic Jacotot, General IP | ||
| JuanCarlos MD, Chief Officer | ||
| Thomas Lingelbach, CEO President | ||
| Gerald Strohmaier, VP Resource | ||
| Peter Buhler, Chief Officer | ||
| Christian Taucher, Head Affairs | ||
| Perry Celentano, Interim Officer | ||
| Joshua Drumm, Vice Relations | ||
| Dipal Patel, Chief Officer | ||
| Susanne EderLingelbach, Head Operations | ||
| Laetitia BachelotFontaine, VP Relations | ||
| Petra Pesendorfer, Chief Officer | ||
| Katrin Dubischar, VP Vaccine | ||
| Franck MBA, Chief Officer |
Valneva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.66) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 1.16 B | ||||
| Shares Outstanding | 69.58 M | ||||
| Shares Owned By Institutions | 0.60 % | ||||
| Number Of Shares Shorted | 47.49 K | ||||
| Price To Book | 4.30 X | ||||
| Price To Sales | 3.85 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Valneva SE ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Valneva SE's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Valneva Se Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Valneva Se Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Valneva SE ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Valneva Stock analysis
When running Valneva SE's price analysis, check to measure Valneva SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valneva SE is operating at the current time. Most of Valneva SE's value examination focuses on studying past and present price action to predict the probability of Valneva SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valneva SE's price. Additionally, you may evaluate how the addition of Valneva SE to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Valneva SE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Valneva SE. If investors know Valneva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Valneva SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 2.218 | Quarterly Revenue Growth (0.79) | Return On Assets (0.10) | Return On Equity (0.58) |
The market value of Valneva SE ADR is measured differently than its book value, which is the value of Valneva that is recorded on the company's balance sheet. Investors also form their own opinion of Valneva SE's value that differs from its market value or its book value, called intrinsic value, which is Valneva SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Valneva SE's market value can be influenced by many factors that don't directly affect Valneva SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Valneva SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Valneva SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valneva SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.